不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma.
The IRE1α Endonuclease Plays a Dual Role in Regulating the XBP1/miRNA-34a Axis and PD-1 Expression within Natural Killer Cells in Hodgkin Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
IRE1α 核酸内切酶成为一个关键角色,同时调控 NK 细胞中的 XBP1s/microRNA-34a-5p/PD-1 轴,这一过程在 HL 中被破坏。靶向 IRE1α 通路有望成为优化霍奇金淋巴瘤治疗中 NK 细胞功能的治疗策略。
霍奇金淋巴瘤(HL)存在主要组织相容性复合体I类分子缺陷,使其易受自然杀伤(NK)细胞抗肿瘤免疫的攻击。尽管HL中PD-1+ NK细胞功能受损,但NK细胞功能障碍的潜在机制仍不清楚。
本研究纳入14例HL患者及SNK10/KHYG-1细胞系,以评估NK细胞对癌细胞的活化作用。通过转录本(PCR)和蛋白表达(流式细胞术)检测活化情况。通过敲低和荧光素酶报告基因实验验证与IRE1α活化相关的调控机制。
我们的研究结果揭示了IRE1α-核酸内切酶通过协调XBP1s/microRNA-34a-5p/PD-1轴在微调NK细胞效应功能中的新作用。当NK细胞遇到癌细胞时,IRE1α核酸内切酶激活microRNA-34a-5p的降解,导致XBP1s和PD-1表达增加。IRE1α-核酸内切酶激活增强NK细胞功能,同时促进PD-1表达。反过来,PD-1直接受microRNA-34a-5p调控,后者与PD-1转录本的3'UTR结合,从而抑制NK细胞表面的PD-1蛋白。重要的是,HL患者NK细胞中IRE1α通路激活受损。
This study involved 14 HL patients and SNK10/KHYG-1 cell lines to assess NK cell activation against cancer cells. Activation was measured through transcript (PCR) and protein expression (flow cytometry). Regulatory mechanisms associated with IRE1α activation were validated through knockdown and luciferase reporter assays.
Our findings reveal a novel role for IRE1α-endonuclease in fine-tuning NK cell effector functions by orchestrating the XBP1s/microRNA-34a-5p/PD-1 axis. When NK cells encounter cancer cells, IRE1α endonuclease activates the decay of microRNA-34a-5p, resulting in increased expression of XBP1s and PD-1. IRE1α-endonuclease activation enhances NK cell functions while promoting PD-1 expression. In turn, PD-1 is directly regulated by microRNA-34a-5p, which binds to the 3'UTR of PD-1 transcript to repress PD-1 protein on the NK cell surface. Importantly, IRE1α-pathway activation is impaired in NK cells from HL patients.
The IRE1α endonuclease emerges as a key player, simultaneously regulating the XBP1s/microRNA-34a-5p/PD-1 axis in NK cells, a process disrupted in HL. Targeting the IRE1α-pathway holds promise as a therapeutic strategy to optimize NK cell functions in Hodgkin lymphoma treatments.
MEMBER ACCOUNT
登录成功会直接打开下一页。